Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1...
Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1–Infected Women
About this item
Full title
Author / Creator
Johnson, Daniel C. , McFarland, Elizabeth J. , Muresan, Petronella , Fenton, Terence , McNamara, James , Read, Jennifer S. , Hawkins, Elizabeth , Bouquin, Pamela L. , Estep, Scharla G. , Tomaras, Georgia D. , Vincent, Carol A. , Rathore, Mobeen , Melvin, Ann J. , Gurunathan, Sanjay and Lambert, John
Publisher
Chicago, IL: The University of Chicago Press
Journal title
Language
English
Formats
Publication information
Publisher
Chicago, IL: The University of Chicago Press
Subjects
More information
Scope and Contents
Contents
Pediatric AIDS Clinical Trials Group protocol 326 is a study of 2 formulations of recombinant canarypox ALVAC vaccine (vCP205) against human immunodeficiency virus type 1 (HIV-1). HIV-1–exposed infants were randomized to receive 1 of 2 formulations of vCP205 or placebo at birth and 4, 8, and 12 weeks. The vaccines were safe. Lymphoproliferative res...
Alternative Titles
Full title
Safety and Immunogenicity of an HIV-1 Recombinant Canarypox Vaccine in Newborns and Infants of HIV-1–Infected Women
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68799329
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68799329
Other Identifiers
ISSN
0022-1899
E-ISSN
1537-6613
DOI
10.1086/498163
